Cargando…

Association of lymphocyte subsets with efficacy and prognosis of immune checkpoint inhibitor therapy in advanced non-small cell lung carcinoma: a retrospective study

BACKGROUND: Immune checkpoint inhibitors (ICIs) have achieved promising effects in patients with non-small cell lung cancer (NSCLC). However, not all patients with NSCLC benefit from immunotherapy. There is an urgent need to explore biomarkers that could predict the survival outcomes and therapeutic...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yan, Yi, Wang, Xinyan, Liu, Chenan, Jia, Junmei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9052648/ https://www.ncbi.nlm.nih.gov/pubmed/35484541 http://dx.doi.org/10.1186/s12890-022-01951-x

Ejemplares similares

The alterations in peripheral lymphocyte subsets predict the efficacy and prognosis of immune checkpoint inhibitors in hepatocellular carcinoma
por: Xie, Qu, et al.
Publicado: (2023)

Peripheral Blood Lymphocyte Subsets Predict the Efficacy of Immune Checkpoint Inhibitors in Non–Small Cell Lung Cancer
por: Miao, Kang, et al.
Publicado: (2022)

Corrigendum: Peripheral blood lymphocyte subsets predict the efficacy of immune checkpoint inhibitors in non– small cell lung cancer
por: Miao, Kang, et al.
Publicado: (2022)

A nomogram model based on peripheral blood lymphocyte subsets to assess the prognosis of non-small cell lung cancer patients treated with immune checkpoint inhibitors
por: Xu, Xiaoling, et al.
Publicado: (2021)

Diagnostic and prognostic nomograms for bone metastasis in small cell lung cancer
por: Liu, Chenan, et al.
Publicado: (2021)

Changes in T lymphocyte subsets predict the efficacy of atezolizumab in advanced non-small cell lung cancer: a retrospective study
por: Wang, Yuyang, et al.
Publicado: (2023)

Advances in immune checkpoint inhibitors therapy for small cell lung cancer
por: Li, Longhui, et al.
Publicado: (2023)

Efficacy of immune checkpoint inhibitors in advanced non-small cell lung cancer harboring BRAF mutations
por: Wang, Haowei, et al.
Publicado: (2023)

Efficacy of immune checkpoint inhibitors in patients with KRAS-mutant advanced non-small cell lung cancer: A retrospective analysis
por: Gu, Xiaodong, et al.
Publicado: (2023)

Peripheral blood nutrient indices as biomarkers for anti‑PD‑1 therapy efficacy and prognosis in patients with advanced gastric cancer
por: Wang, Xinyan, et al.
Publicado: (2023)

Pretreatment neutrophil-to-lymphocyte ratio predicts treatment efficacy and prognosis of cytotoxic anticancer drugs, molecular targeted drugs, and immune checkpoint inhibitors in patients with advanced non-small cell lung cancer
por: Ishihara, Masashi, et al.
Publicado: (2021)

Prognostic roles of hematological indicators for the efficacy and prognosis of immune checkpoint inhibitors in patients with advanced tumors: a retrospective cohort study
por: Zheng, Fei, et al.
Publicado: (2023)

Retrospective Efficacy Analysis of Immune Checkpoint Inhibitor Rechallenge in Patients with Non-Small Cell Lung Cancer
por: Katayama, Yuki, et al.
Publicado: (2019)

Circulating T lymphocyte subsets, cytokines, and immune checkpoint inhibitors in patients with bipolar II or major depression: a preliminary study
por: Wu, Wei, et al.
Publicado: (2017)

Efficacy of Immune Checkpoint Inhibitor Monotherapy for Advanced Non-Small-Cell Lung Cancer with ALK Rearrangement
por: Oya, Yuko, et al.
Publicado: (2020)

Efficacy of immune-checkpoint inhibitors in advanced non-small cell lung cancer patients with different metastases
por: Qiao, Meng, et al.
Publicado: (2021)

Assessment of neutrophil subsets and immune checkpoint inhibitor expressions on T lymphocytes in liver transplantation: A preliminary study beyond the neutrophil-lymphocyte ratio
por: Riff, Arnaud, et al.
Publicado: (2023)

The role of ERBB4 mutations in the prognosis of advanced non-small cell lung cancer treated with immune checkpoint inhibitors
por: Hu, Xilin, et al.
Publicado: (2021)

Novel predictors of immune checkpoint inhibitor response and prognosis in advanced non‐small‐cell lung cancer with bone metastasis
por: Asano, Yohei, et al.
Publicado: (2023)

Retrospective efficacy analysis of immune checkpoint inhibitors in patients with EGFR‐mutated non‐small cell lung cancer
por: Yamada, Tadaaki, et al.
Publicado: (2019)

Indirect comparison of efficacy and safety between immune checkpoint inhibitors and antiangiogenic therapy in advanced non–small-cell lung cancer
por: Chen, Jin-Hua, et al.
Publicado: (2018)

Effect of sex on the efficacy of patients receiving immune checkpoint inhibitors in advanced non‐small cell lung cancer
por: Wang, Chengdi, et al.
Publicado: (2019)

Recent advances in immune checkpoint inhibitors for non-small lung cancer treatment
por: Altaf, Reem, et al.
Publicado: (2022)

Retrospect and Prospect for Lung Cancer in China: Clinical Advances of Immune Checkpoint Inhibitors
por: Lu, Shun, et al.
Publicado: (2019)

Immune Checkpoint Inhibitor-Induced Lymphocytic Esophagitis
por: Amin, Shefali, et al.
Publicado: (2023)

Immune checkpoint inhibitor‐associated interstitial lung diseases correlate with better prognosis in patients with advanced non‐small‐cell lung cancer
por: Sugano, Teppei, et al.
Publicado: (2020)

Efficacy and safety of maintenance immune checkpoint inhibitors with or without pemetrexed in advanced non-squamous non-small cell lung cancer: a retrospective study
por: Gu, Xiaodong, et al.
Publicado: (2022)

Immune checkpoint inhibitor rechallenge in advanced or metastatic non-small cell lung cancer: a retrospective cohort study
por: Xu, Ziyi, et al.
Publicado: (2022)

The Relationship between Lymphocyte Subsets and the Prognosis and Genomic Features of Lung Cancer: A Retrospective Study
por: Dai, Shuiping, et al.
Publicado: (2021)

Impact of bowel movement condition on immune checkpoint inhibitor efficacy in patients with advanced non‐small cell lung cancer
por: Katayama, Yuki, et al.
Publicado: (2019)

Association of the advanced lung cancer inflammation index (ALI) with immune checkpoint inhibitor efficacy in patients with advanced non-small-cell lung cancer
por: Mountzios, G., et al.
Publicado: (2021)

Efficacy and predictors of rechallenge with immune checkpoint inhibitors in non‐small cell lung cancer
por: Takahara, Yutaka, et al.
Publicado: (2022)

Predictability of early changes in derived neutrophil-to-lymphocyte ratio and neutrophil-to-lymphocyte ratio in patients with advanced non-small cell lung cancer treated with immune checkpoint inhibitors
por: Lim, Jeong Uk, et al.
Publicado: (2021)

A cohort study of the efficacy and safety of immune checkpoint inhibitors plus anlotinib versus immune checkpoint inhibitors alone as the treatment of advanced non-small cell lung cancer in the real world
por: Shi, Yue, et al.
Publicado: (2022)

Comparison of a combination of chemotherapy and immune checkpoint inhibitors and immune checkpoint inhibitors alone for the treatment of advanced and metastatic non‐small cell lung cancer
por: Kuo, Chih‐Hsi Scott, et al.
Publicado: (2019)

Subunits of ARID1 serve as novel biomarkers for the sensitivity to immune checkpoint inhibitors and prognosis of advanced non-small cell lung cancer
por: Sun, Dantong, et al.
Publicado: (2020)

Safety and efficacy of immune checkpoint inhibitors in non-small cell lung cancer patients with preexisting antinuclear antibodies: a retrospective cohort study
por: Zhang, Dongming, et al.
Publicado: (2022)

Neutrophil to lymphocyte ratio influences impact of steroids on efficacy of immune checkpoint inhibitors in lung cancer brain metastases
por: Lauko, Adam, et al.
Publicado: (2021)

Neutrophil–lymphocyte ratio (NLR) predicted prognosis for advanced non-small-cell lung cancer (NSCLC) patients who received immune checkpoint blockade (ICB)
por: Ren, Fangping, et al.
Publicado: (2019)

The Correlation between the Use of the Proton Pump Inhibitor and the Clinical Efficacy of Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer
por: Hu, Da-Hai, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_q60qkn2c7j6fo6ckakirg6v4r8